China: Uncovering opportunities within the medical beauty industry

China is poised to become the world’s largest medical aesthetic service market in 2021. As a booming live streaming economy heightens the desire to look attractive, the growing acceptance of aesthetic treatments by younger consumers results in a longer consumer life cycle. This phenomenon potentially creates attractive investment opportunities in the industry’s unique ecosystem of filler manufacturers, internet platforms, consumer finance apps and aesthetic service providers.

China has become one of the fastest growing medical aesthetic service markets in the world, ranked second in terms of market size in 2017, and poised to become the world’s largest market in 2021. According to Frost & Sullivan, the total revenues of China’s medical aesthetic services industry reached USD17.7 billion in 2018, growing at a compounded average growth rate (CAGR) of 23.6% from 2014. Revenues are forecasted to reach USD52.4 billion by 2023.

Thanks for subscribing!

Follow us :

Medical aesthetic services are elective medical procedures that specialise in improving cosmetic appearances and can be divided into surgical and non-surgical treatments. Surgical medical aesthetic services are often referred to as plastic surgeries while non-surgical medical aesthetic services can include injection procedures (e.g. Botulinum toxin1 (botox) and Hyaluronic Acid2 (HA) injections), laser as well as other energy-based skin treatments (e.g. Thermage).

Growing beauty enthusiasts

Compared to developed countries such as the US where anti-aging treatments are more popular, younger consumers make up most of the demand in China as the mainland’s rising social media usage and booming live streaming economy have heightened the desire to look young and attractive. Exposure to medical aesthetic treatment at a younger age, when consumers are more prone to form entrenched habits, potentially creates a longer consumer life cycle and ongoing demand.

China’s rising disposable income should also help lift penetration rates. Per capita disposable income in China increased from USD2,933 in 2014 to USD4,106 in 2018, a CAGR of 8.8%3. Growth is expected to continue at a CAGR of 7.7% from 2018 to 2023. Meanwhile, about 12 per 1000 people in China has undergone medical aesthetic treatments in 2017. This is low compared to numbers for South Korea (80.4), the US (50.1), Brazil (43.6) and Japan (27.0). China’s significantly lower penetration rate highlights its tremendous growth potential, particularly in the lower tier cities.

Non-surgical procedures offer a lift

In China, while surgical aesthetic procedures currently account for a larger share of medical aesthetic services, the share of non-surgical aesthetic procedures is expected to grow at a faster rate as the range of treatments increases. See Fig. 1. The demand for non-surgical aesthetic procedures is also boosted by the perceived lower risks and shorter recovery times.

Fig. 1: Growth of China’s medical aesthetic service market


Botox and HA injections currently make up the bulk of the non-surgical procedures in China. In 1998, researchers from the Shandong Pharmaceutical Research Institute began domestic production of HA derma fillers via the fermentation process. Today, China has a number of local HA derma filler manufacturers which are established and based in Shandong, some of which had sought funding by listing on the Chinese stock market in recent years. Currently, China’s HA derma filler market is dominated by foreign brands such as LG (Korea), Allergan (US), Humedix (Korea) and Q-Med (Switzerland) while the top three domestic brands are Haohai, Imeik and Bloomage.

According to Frost & Sullivan, domestic brands of cosmetic injectables in China grew rapidly at a CAGR of +32% during 2014-2018, higher than the +19% CAGR of imported brands. Among the 15 manufacturers (eight domestic and seven imported) of injectable HA approved by China’s National Medical Products Administration (NMPA), the top 3 domestic brands secured 42.4% market share in terms of sales volume in 2018, but only 23.4% share in terms of sales revenue. We believe that quality domestic players can gain further market share from imported brands by improving on their product range, quality and pricing.

Fig. 2: Breakdown of China’s Hyaluronic Acid filler market (2020E)


China’s botox market is currently smaller than its HA market – contrary to what is typically seen in other countries. This is due to China’s lengthy approval process where it can take up to eight years for botox products to be approved. Currently, the only two approved botox products in China – Hengli and Allergan, make up a RMB3 billion market. In October 2020, a botox product produced by Hugel, a biopharmaceutical company in South Korea, was approved for sale in China, making it South Korea’s first botox product to be approved by China’s NMPA. We believe that China’s botox market has the potential to become a RMB10 billion market in the near future. Meanwhile with a number of imported and domestically produced products still at the approval stage, a leading domestic player has yet to emerge in this space.

Opportunities within the beauty ecosystem

With a greater focus on customer acquisition, publicity, better service quality, improved brand recognition and an enhanced safety record, an increasing number of Chinese consumers are viewing medical aesthetic procedures as a natural extension and upgrade of traditional non-medical wellness procedures.

There are various avenues for investors to gain exposure to China’s growing medical aesthetics market. Local manufacturers of HA injectables that are able to deliver more effective treatments that meet the increasingly segmented market demand may present compelling opportunities. HA manufacturers have been able to produce differentiated products that offer shaping, filling or lifting effects. Cross-linked HA for example, makes HA more durable and firmer in consistency. Although incumbents may have an early mover’s advantage, late entrants can seize market share through product innovation. At the point of writing, Poly-L-lactic acid-based filling products4 as well as emulsifier-based fat dissolving injections have been recently introduced in China. Hence investors will need to stay abreast of market developments given the rapidly evolving market dynamics. Besides having an exciting pipeline of products, consumer education is also important. As such, manufacturers that are willing to invest in an experienced sales force would be able to improve their engagement with the critical network of medical institutions and physician groups and hence have a competitive edge.

The asymmetry of information and large number of aesthetics service providers have created a role for internet platforms that offer customer reviews and specialised information. Consumer finance applications targeted at helping consumers pay for medical aesthetics treatments have also emerged. Over time, consolidation of China’s aesthetics services providers may also create interesting downstream investment opportunities.

This is the second of six articles in Eastspring’s 2021 Asian Expert Series. In this new series which focuses on China, our investment teams offer insights into the opportunities and challenges facing China as it rolls out its 14th Five-Year Plan.

Click here to read other articles in our Asian Expert Series. 

This document is produced by Eastspring Investments (Singapore) Limited and issued in:

Singapore by Eastspring Investments (Singapore) Limited (UEN: 199407631H)

Australia (for wholesale clients only) by Eastspring Investments (Singapore) Limited (UEN: 199407631H), which is incorporated in Singapore, is exempt from the requirement to hold an Australian financial services licence and is licensed and regulated by the Monetary Authority of Singapore under Singapore laws which differ from Australian laws

Hong Kong by Eastspring Investments (Hong Kong) Limited and has not been reviewed by the Securities and Futures Commission of Hong Kong.

Indonesia by PT Eastspring Investments Indonesia, an investment manager that is licensed, registered and supervised by the Indonesia Financial Services Authority (OJK).

Malaysia by Eastspring Investments Berhad (200001028634/ 531241-U) and Eastspring Al-Wara’ Investments Berhad (200901017585 / 860682-K).

Thailand by Eastspring Asset Management (Thailand) Co., Ltd.

United States of America (for institutional clients only) by Eastspring Investments (Singapore) Limited (UEN: 199407631H), which is incorporated in Singapore and is registered with the U.S Securities and Exchange Commission as a registered investment adviser.

European Economic Area (for professional clients only) and Switzerland (for qualified investors only) by Eastspring Investments (Luxembourg) S.A., 26, Boulevard Royal, 2449 Luxembourg, Grand-Duchy of Luxembourg, registered with the Registre de Commerce et des Sociétés (Luxembourg), Register No B 173737.

United Kingdom (for professional clients only) by Eastspring Investments (Luxembourg) S.A. - UK Branch, 10 Lower Thames Street, London EC3R 6AF.

Chile (for institutional clients only) by Eastspring Investments (Singapore) Limited (UEN: 199407631H), which is incorporated in Singapore and is licensed and regulated by the Monetary Authority of Singapore under Singapore laws which differ from Chilean laws.

The afore-mentioned entities are hereinafter collectively referred to as Eastspring Investments.

The views and opinions contained herein are those of the author, and may not necessarily represent views expressed or reflected in other Eastspring Investments’ communications. This document is solely for information purposes and does not have any regard to the specific investment objective, financial situation and/or particular needs of any specific persons who may receive this document. This document is not intended as an offer, a solicitation of offer or a recommendation, to deal in shares of securities or any financial instruments. It may not be published, circulated, reproduced or distributed without the prior written consent of Eastspring Investments. Reliance upon information in this document is at the sole discretion of the reader. Please carefully study the related information and/or consult your own professional adviser before investing.

Investment involves risks. Past performance of and the predictions, projections, or forecasts on the economy, securities markets or the economic trends of the markets are not necessarily indicative of the future or likely performance of Eastspring Investments or any of the funds managed by Eastspring Investments.

Information herein is believed to be reliable at time of publication. Data from third party sources may have been used in the preparation of this material and Eastspring Investments has not independently verified, validated or audited such data. Where lawfully permitted, Eastspring Investments does not warrant its completeness or accuracy and is not responsible for error of facts or opinion nor shall be liable for damages arising out of any person’s reliance upon this information. Any opinion or estimate contained in this document may subject to change without notice.

Eastspring Investments companies (excluding joint venture companies) are ultimately wholly owned/indirect subsidiaries of Prudential plc of the United Kingdom. Eastspring Investments companies (including joint venture companies) and Prudential plc are not affiliated in any manner with Prudential Financial, Inc., a company whose principal place of business is in the United States of America or with the Prudential Assurance Company Limited, a subsidiary of M&G plc (a company incorporated in the United Kingdom).